253 related articles for article (PubMed ID: 20600672)
1. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma.
Kim KY; Ju WK; Hegedus B; Gutmann DH; Ellisman MH
Neuroscience; 2010 Sep; 170(1):178-88. PubMed ID: 20600672
[TBL] [Abstract][Full Text] [Related]
2. Optic nerve dysfunction in a mouse model of neurofibromatosis-1 optic glioma.
Hegedus B; Hughes FW; Garbow JR; Gianino S; Banerjee D; Kim K; Ellisman MH; Brantley MA; Gutmann DH
J Neuropathol Exp Neurol; 2009 May; 68(5):542-51. PubMed ID: 19525901
[TBL] [Abstract][Full Text] [Related]
3. The impact of coexisting genetic mutations on murine optic glioma biology.
Kaul A; Toonen JA; Gianino SM; Gutmann DH
Neuro Oncol; 2015 May; 17(5):670-7. PubMed ID: 25246427
[TBL] [Abstract][Full Text] [Related]
4. NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.
Toonen JA; Anastasaki C; Smithson LJ; Gianino SM; Li K; Kesterson RA; Gutmann DH
Hum Mol Genet; 2016 May; 25(9):1703-13. PubMed ID: 26908603
[TBL] [Abstract][Full Text] [Related]
5. Defining the temporal course of murine neurofibromatosis-1 optic gliomagenesis reveals a therapeutic window to attenuate retinal dysfunction.
Toonen JA; Ma Y; Gutmann DH
Neuro Oncol; 2017 Jun; 19(6):808-819. PubMed ID: 28039362
[TBL] [Abstract][Full Text] [Related]
6. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma.
Solga AC; Gianino SM; Gutmann DH
Oncogene; 2014 Jan; 33(3):289-99. PubMed ID: 23318450
[TBL] [Abstract][Full Text] [Related]
7. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology.
Toonen JA; Solga AC; Ma Y; Gutmann DH
J Exp Med; 2017 Jan; 214(1):17-25. PubMed ID: 27923908
[TBL] [Abstract][Full Text] [Related]
8. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.
Bajenaru ML; Hernandez MR; Perry A; Zhu Y; Parada LF; Garbow JR; Gutmann DH
Cancer Res; 2003 Dec; 63(24):8573-7. PubMed ID: 14695164
[TBL] [Abstract][Full Text] [Related]
9. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity.
Brown JA; Gianino SM; Gutmann DH
J Neurosci; 2010 Apr; 30(16):5579-89. PubMed ID: 20410111
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth.
Simmons GW; Pong WW; Emnett RJ; White CR; Gianino SM; Rodriguez FJ; Gutmann DH
J Neuropathol Exp Neurol; 2011 Jan; 70(1):51-62. PubMed ID: 21157378
[TBL] [Abstract][Full Text] [Related]
11. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
12. Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.
Warrington NM; Woerner BM; Daginakatte GC; Dasgupta B; Perry A; Gutmann DH; Rubin JB
Cancer Res; 2007 Sep; 67(18):8588-95. PubMed ID: 17875698
[TBL] [Abstract][Full Text] [Related]
13. Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation.
Pong WW; Higer SB; Gianino SM; Emnett RJ; Gutmann DH
Ann Neurol; 2013 Feb; 73(2):303-8. PubMed ID: 23424002
[TBL] [Abstract][Full Text] [Related]
14. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation.
Daginakatte GC; Gianino SM; Zhao NW; Parsadanian AS; Gutmann DH
Cancer Res; 2008 Dec; 68(24):10358-66. PubMed ID: 19074905
[TBL] [Abstract][Full Text] [Related]
15. RNA Sequencing of Tumor-Associated Microglia Reveals Ccl5 as a Stromal Chemokine Critical for Neurofibromatosis-1 Glioma Growth.
Solga AC; Pong WW; Kim KY; Cimino PJ; Toonen JA; Walker J; Wylie T; Magrini V; Griffith M; Griffith OL; Ly A; Ellisman MH; Mardis ER; Gutmann DH
Neoplasia; 2015 Oct; 17(10):776-88. PubMed ID: 26585233
[TBL] [Abstract][Full Text] [Related]
16. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging.
Su W; Xing R; Guha A; Gutmann DH; Sherman LS
Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023
[TBL] [Abstract][Full Text] [Related]
17. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
19. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
20. Treatment during a developmental window prevents NF1-associated optic pathway gliomas by targeting Erk-dependent migrating glial progenitors.
Jecrois ES; Zheng W; Bornhorst M; Li Y; Treisman DM; Muguyo D; Huynh S; Andrew SF; Wang Y; Jiang J; Pierce BR; Mao H; Krause MK; Friend A; Nadal-Nicolas F; Stasheff SF; Li W; Zong H; Packer RJ; Zhu Y
Dev Cell; 2021 Oct; 56(20):2871-2885.e6. PubMed ID: 34428430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
